An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics

Pomalidomide is an immunomodulatory drug and the dosage of 4 mg per day taken orally on days 1‐21 of repeated 28‐day cycles has been approved in the European Union and United States to treat patients with relapsed/refractory multiple myeloma. Because pomalidomide is extensively metabolized prior to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Wang, Xiaomin, Liu, Liangang, Zhang, Chengyue, Gomez, Diana, Reyes, Josephine, Palmisano, Maria, Zhou, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585766/
https://www.ncbi.nlm.nih.gov/pubmed/29746728
http://dx.doi.org/10.1002/cpdd.470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585766/
https://www.ncbi.nlm.nih.gov/pubmed/29746728
http://dx.doi.org/10.1002/cpdd.470

Ejemplares similares